MedPath

A multi-centred, randomized, controlled trial comparing weight loss in endoscopically implanted duodenal-jejunal bypass liners vs intragastric balloons vs a sham procedure

Not Applicable
Conditions
E66
E11
Obesity
Type 2 diabetes mellitus
Registration Number
DRKS00011036
Lead Sponsor
niversität Leipzig
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting stopped after recruiting started
Sex
All
Target Recruitment
33
Inclusion Criteria

Age = 18 years
- BMI = 35 or BMI = 30 kg/m² with obesity related co-morbidities such as diabetes
- Dietary consultation was received, but was ineffective
- written informed consent
- indication for long-tern PPI-therapy

Exclusion Criteria

- malignant disease
- peptic ulcer
- large hiatus hernia
- gastrointestinal disease
- previous gastric or bariatric surgery
- high risk of gastrointestinal bleeding
- symptomatic gallstones
- contraindication for general anaesthesia
- contraindication for devices according to manufacturer
- contraindication for proton pump inhibitors (PPIs)
- non controlled GERD (gastroesophageal reflux disease)
- suspected lack of compliance
- drug or alcohol abuse
- pregnant or nursing women
- fertile women without appropriate contraceptive measures while participating in the trial
- participation in other interventional trials
- psychological/mental or other inabilities to supply required information (e.g. fill out the questionnaire or follow dietary recommendations due to dementia, language difficulties)

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
successful weight loss 12 months after removal of the medical product<br>(Note: The scheduled removal of the intragastric balloon is after 6 months, the EndoBarrier after 12 months. The primary EP is determined for the intragastric balloon and the sham-control after 18 months, and for the endo barrier after 24 months.)
Secondary Outcome Measures
NameTimeMethod
- Percentage weight loss 12 months after removal<br>- successful weight loss (=10%) and percentage weight loss after 6 months<br>- successful weight loss (=10%) and percentage weight loss at removal of medical product<br>- remission and reduction of concomitant diseases at removal and 12 months after removal<br>- change of the HbA1c-value at initial values >6,5% at removal and 12 months after removal<br>- changes in quality of life (SF-36), physical activity (IPAQ) and body composition (BIA (Bioelectrical impedance analysis)) after 6, 12 and 24 months<br>- complication rate of the endoscopic procedures in the periods 0-6 months or removal, 6-12 months or removal and time after removal<br>- comparison of success”12 months after removal (success is defined as excess weight loss of et least 25%)
© Copyright 2025. All Rights Reserved by MedPath